Patients with MDS-SF3B1 had significantly more DNMT3A (16% vs. 6%, P = 0.029) and TET2 mutations (32% vs. 14%, P = 0.004) but fewer STAG2 mutation (2% vs. 9%, P = 0.068) than did those with MDS-LB, while fewer of them harbored SRSF2 mutations when compared to those with MDS-LB and RS (3% vs. 25%, P = 0.014) (Supplementary Table 4b). This evidence concerns the gene STAG2 and myelodysplastic syndrome.